Mental Health Clinician (Mar 2021)

Opioid toxicity due to CNS depressant polypharmacy: A case report

  • Christine Lee,
  • Annabelle Wanson, MD, FRCPC,
  • Sarah Frangou, BSc, MD,
  • David Chong, BSc, MSc, BMBS,
  • Katelyn Halpape, BSP, ACPR, PharmD, BCPP

DOI
https://doi.org/10.9740/mhc.2021.03.070
Journal volume & issue
Vol. 11, no. 2
pp. 70 – 74

Abstract

Read online

The interaction between methadone and central nervous system depressants can cause serious adverse effects, including profound sedation, respiratory depression, coma, and death. This poses a challenge in the treatment of patients with concurrent psychiatric and substance use disorders as the combined use is often unavoidable. We report a case of a patient with opioid use disorder, mood disorder unspecified, chronic pain, and chronic obstructive pulmonary disease who experienced 2 serious episodes of CNS and respiratory depression due to polypharmacy-induced opioid toxicity. Careful consideration of pharmacokinetics, pharmacodynamics, and patient-specific factors was imperative to identify the suspected contributing medications: methadone, lorazepam, divalproex, gabapentin, and cyclobenzaprine. Cognitive and system factors that contributed to these adverse events and strategies to mitigate risk of recurrence were also identified.

Keywords